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Abstract. Neuropathic pain (NP) often occurs during the course of leprosy, and screening tools to differentiate NP
from non-NP are often used. However, their performance varies in different settings. The most frequently used scales
are the Douleur Neuropathique in 4 questions (DN4) and the Leeds assessment of neuropathic symptoms and signs
(LANSS) questionnaires. Thus, we conducted a study to evaluate the agreement between DN4 and LANSS question-
naires to classify NP in 195 leprosy patients attending two reference centers in Sergipe, Brazil. The DN4 and LANSS
classified 166 and 110 patients, respectively, as having NP. One hundred and seven (54.8%) were classified as NP by
both questionnaires; 59 (30.2%) solely by the DN4 questionnaire and three (1.5%) solely by the LANSS. The agree-
ment of the questionnaires was 66.2% (weak agreement, Kappa = 0.30). Although both questionnaires identified a high
proportion of NP, the development of more robust instruments is necessary to ensure the accuracy of diagnosis of
leprosy patients classified as having NP.
INTRODUCTION
Pain is one of the main reasons why people seek medical
services. Acute pain leads patients to attend emergency ser-
vices, whereas chronic pain is a major cause of ambulatory
consultations. It is estimated that one in five adults experi-
ence pain at any one time and one in 10 patients suffer of
chronic pain.1
Neuropathic pain (NP), or “pain arising as a direct conse-
quence of a lesion or disease affecting the somatosensory
system,”2 is present in 1–18% of patients with pain3 and
occurs in a wide range of diseases.4 Between 11% and 79%
of patients with leprosy are reported to have NP4–8; and
other types of pain, such as nociceptive and inflammatory
pain may occur.9 The proper classification of pain is essential
for the selection of therapy, as nociceptive pain responds to
steroids and anti-inflammatory drugs10; inflammatory pain
can be treated with nonsteroidal anti-inflammatory drugs,9
and NP responds to tricyclic antidepressants, anticonvulsants,
and opioids.11
Although NP is a common complication of leprosy, its
identification is often neglected. Screening tools to identify
NP often used by nonspecialists include the Douleur Neuro-
pathique in 4 questions (DN4) and the Leeds assessment of
neuropathic symptoms and signs (LANSS) for patients with
chronic pain questionnaire.12 However, few studies have
evaluated their use in leprosy.
METHODS
We evaluated the agreement of the DN4 and LANSS
questionnaires in leprosy patients using a cross-sectional sur-
vey of patients > 15 years of age with a diagnosis of leprosy
attending the leprosy reference centers in Sergipe State,
northeast Brazil, between February and June 2015.
All consecutive patients attending the University Hospital
Clinic and the Leprosy and Tuberculosis Reference Center
reporting having pain at the time of consultation were
invited to participate. Patients were enrolled if they were
receiving multidrug therapy (MDT) or had completed treat-
ment but were attending the services to complete routine
follow-up consultations. Patients with diabetes, alcoholism,
human immunodeficiency virus infection, or severe mental
or physical conditions interfering with the assessment of pain
were excluded. The patient’s demographic and clinical char-
acteristics (leprosy classification, disability grade, leprosy
reaction) were obtained using structured questionnaires.
Patients were classified according to World Health Organiza-
tion (WHO) criteria as paucibacillary (PB) (≤ 5 skin lesions
and/or only one affected nerve trunk) or multibacillary (MB)
leprosy (> 5 skin lesions and/or > 1 affected nerve trunk).13
Leprosy reactions were classified as type 1 (acute episodes
of skin or nerves inflammation) or type 2 (appearance
of painful skin nodules with or without neuritis).13 WHO
categorizes leprosy-related disability as having no disabil-
ity (grade 0); decreasing or loss of sensibility in the eyes,
hands, or feet without visible deformity (grade 1); and loss
of sensation and visible deformities of the eyes, hands, or
feet (grade 2).14
Participants were assessed for skin sensory loss and
enlargement of peripheral nerves by assessing touch, pin-
prick sensations, mechanical allodynia, and nerve palpation.
Two trained research assistants applied the LANSS and
DN4 questionnaires in Portuguese. The LANSS question-
naire evaluates five symptoms and two sensory tests for the
presence of allodynia, hyperesthesia, or hypoesthesia to pin-
prick.12 This tool indicates that “if (the) score < 12, neuro-
pathic mechanisms are unlikely to be contributing to the
patient’s pain” and “if (the) score ≥ 12, neuropathic mecha-
nisms are likely to be contributing to the patient’s pain.”12
The DN4 questionnaire distinguishes NP and nonneuro-
pathic (non-NP) pain using seven items related to symp-
toms (burning, painful cold, electric shock, tingling, pins
and needles, and itching) and three items related to the
clinical examination (hypoesthesia to touch and prick and
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brushing).12 The score ranges from 0 to 10, with scores ≥ 4
suggesting NP.12
Categorical variables were described using frequencies
and percentages. The agreement between the two instru-
ments was calculated by dividing the number of concordant
positive and concordant negative cases by the total number
of patients and estimating Kappa statistics.15 P values < 5%
were considered statistically significant.
The Human Research Ethics Committee of the Federal
University of Sergipe (CAAEn.31078114.3.0000.5546) approved
the study protocol. Written informed consent was obtained
from all participants. Parents or guardians provided written
informed consent for minors.
RESULTS
One hundred and ninety-five patients with a median
(interquartile range) age of 49 (25–75) years were enrolled,
of whom 120 (61.5%) were male. One hundred and fifty-
nine (81.5%) had MB and 35 (17.9%) had PB leprosy.
Eighty-two (42%) patients were receiving MDT and 113
(58%) had completed treatment. In total, 131 (67.2%) patients
had leprosy-related disabilities and 130 (66.7%) had leprosy
reactions (Table 1).
The DN4 questionnaire classified 166 (63.8%) patients
as having NP, with numbness (163, 98.2%), tingling (150,
90.4%), pins and needles (137, 82.5%), and prick hypo-
esthesia (137, 82.5%) being most frequently reported
(Table 2). The LANSS questionnaire classified 110 (42.3%)
patients as having NP. The symptoms more frequently
reported were pins and needles, electric shocks, and tin-
gling (110, 100%), shootings (102, 92.7%), and burnings
(95, 86.4%), as shown in Table 2.
The DN4 questionnaire classified 138 (86.8%) of 159 MB
leprosy patients as having NP, whereas the LANSS classified
93 (58.5%) as having NP. Among the 131 patients who had
leprosy reactions, 74 (56.5%) were classified as having NP
by both DN4 and LANSS questionnaires.
The agreement of the scales to classify patients as having
NP was 66% among PB leprosy patients (Kappa = 0.32, P =
0.02), 69% among MB patients (Kappa = 0.30, P < 0.001),
67% among the patients without leprosy reactions (Kappa =
0.30, P = 0.003), and 68% among the patients with leprosy
reactions (Kappa = 0.30, P < 0.001). The overall agreement
of the two scales is shown in Table 3. One hundred and
seven (54.8%) patients were classified as NP by both ques-
tionnaires; 59 (30.2%) solely by the DN4 questionnaire;
three (1.5%) solely by LANSS, and 26 (13.3%) as non-NP
by both scales. The overall agreement was 66.2% (129/
195), with a Kappa of 0.30 (P < 0.001) corresponding to
weak agreement.
DISCUSSION
The recognition of NP in leprosy patients is important
for the selection of adequate treatment. The reported
prevalence of NP in leprosy patients, however, varies
widely.4,8,9,16,17 These estimates are likely to vary by the type
of participants and the diagnostic tools used.9 The DN4
questionnaire is reported to have high sensitivity (100%)4
but variable specificity (45–92%)4–6,18; whereas the LANSS
questionnaire is reported to have slightly lower sensitivity
(85%) and specificity (42%).4
Although screening tools offer screening guidance for the
potential presence of NP, their use should not replace clinical
judgment, which is considered the reference standard by
experienced clinicians. There are very few studies compar-
ing the performance of the DN4 and LANSS question-
naires in patients with leprosy.4 Although in this study, both
TABLE 1
Demographic and clinical characteristics of study participants
Variables N = 195
Age, median (IQR) 49 (36–59)
Sex, male, n (%) 120 (61.5)
Income, n (%)
0–2 minimum salaries 185 (95.4)
≥ 3 minimum salaries 9 (4.6)
Schooling
0–4 years 150 (76.9)
5–8 years 39 (20.0)
≥ 9 years 6 (3.1)
Rural residency 41 (21.0)
MB leprosy (%) 159 (81.9)
Leprosy reactions 157 (60.4)
Presence of disability 131 (67.2)
IQR = interquartile range; MB = multibacillary.
TABLE 2
DN4 and LANSS questionnaire responses of patients classified as
having NP and non-NP
DN4 items
Score ≥ 4 (NP)
N (%)
Score < 4 (non-NP)
N (%)
Burning 132 (79.5) 6 (20.7)
Painful cold 56 (33.7) 0 (0)
Electric shocks 133 (80.1) 11 (37.9)
Tingling 150 (90.4) 9 (31)
Pins and needles 137 (82.5) 6 (20.7)
Numbness 163 (98.2) 14 (48.3)
Itching 81 (48.8) 3 (10.3)
Touch hypoesthesia 127 (76.5) 6 (20.7)
Prick hypoesthesia 137 (82.5) 8 (27.6)
Pain increasing by
brushing (allodynia)
31 (18.7) 1 (3.4)
LANSS items Score ≥ 12 (NP)N (%)
Score < 12 (non-NP)
N (%)
Pins and needles,
electric shocks and tingling
110 (100) 64 (75.3)
Autonomic changes 88 (80) 7 (8.2)
Pain evoked by light touching 33 (30) 5 (5.9)
Electric shocks or shooting 102 (92.7) 51 (60)
Hot or burning 95 (86.4) 47 (55.3)
Allodynia 18 (16.4) 0 (0)
Raised pin prick threshold 92 (83.6) 55 (64.7)
DN4 = Douleur Neuropathique in 4 questions; LANSS = Leeds assessment of neuro-
pathic symptoms and signs; NP = neuropathic pain.
TABLE 3





Positive 107 (53.3%) 3 (1.5%) 110
Negative 59 (30.2%) 26 (13.3%) 85
Total 166 29 195
DN4 = Douleur Neuropathique in 4 questions; LANSS = Leeds assessment of neuro-
pathic symptoms and signs; Kappa = 0.30; P < 0.001.
757DN4 AND LANSS TO CLASSIFY NEUROPATHIC PAIN IN LEPROSY
questionnaires classified a high proportion of patients as hav-
ing NP, they presented a high level of disagreement.
Most studies use different reference standards to assign
patients as correctly and incorrectly classified and the lack of
a uniform reference standard impedes their comparison. The
high level of disagreement reported here indicates that stud-
ies using only one scale present risk of misclassifying or miss-
ing patients with NP because the scales seems to select
different patients for referral.
A study evaluating the agreement between the self-
completed LANSS, which does not include clinical exami-
nations, and the DN4 questionnaire in patients with low
back-related leg pain, reported that the DN4 was slightly more
discriminatory to identify NP.19 A further study applying the
DN4 with and without clinical examination in the same patients
identified that omitting the clinical component led to differences
in sensitivity and specificity and reduced the diagnostic accu-
racy when compared with an expert-led clinical evaluation.20
In our study, both questionnaires included a brief clinical
examination. The DN4 questionnaire classified 25% more
patients as having NP than the LANSS. Perhaps, its higher
propensity to classify patients as NP is due to the additional
parameters assessed such as numbness, itching, and soft
touch threshold.7 In addition, the DN4 questionnaire is
composed of short questions and symptoms that are well
distributed throughout the questionnaire, which facilitate the
patient’s understanding of the questions.
Studies based on populations attending reference and spe-
cialized centers are more likely to have leprosy lesions and
complications than patients treated at primary health centers
and therefore are more likely to have NP.7,8 There is also a
well-established association between the presence of leprosy
reactions and pain,4,9 and it is presumed that NP develops
gradually as a consequence of the regenerative processes
leading to overactive peripheral nociceptive fibers resulting
from chronic neural inflammation.4
The main limitation of this study therefore concerns with
sample selection, as participants were attending reference
centers and were more likely to have NP than patients
attending primary care facilities. Scales that have a high pro-
portion of false-positive results may return overoptimistic
assessments in this context. Furthermore, the scales evalu-
ated only distinguish NP from non-NP pain. However,
patients with leprosy often have other non-NP pain types
over the clinical course of their illness, and further scales
are needed to fully classify these patients.
The instruments assessed here are widely used to help non-
specialist health-service providers to identify patients who may
have NP. They are easy to use in locations where there are no
specialists available to screen patients for referral to special-
ized centers. Despite their lack of agreement, health staff
does not have better scales available and will need to con-
tinue using them until improved tools become available. How-
ever, staff needs to be aware of their significant limitations.
In conclusion, DN4 and LANSS questionnaires have a
substantial degree of disagreement to classify NP in leprosy
patients. More robust and accurate screening tools suitable
for use by nonspecialist health providers to identify NP
are needed.
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